Among a multitude of tests available to evaluate patients with suspected prostate cancer, modern imaging techniques seem to be the most relevant and their use is growing fast. Magnetic resonance imaging (MRI) technology is the most important imaging tool for identifying early prostate cancers, characterising tumours, helping in patient risk stratification and enabling focused use of biopsy. In addition, recent advances in transrectal ultrasonography of the prostate, such as realtime tissue elastography and contrast-enhanced ultrasonography, allow better identification of cancer. The optimal prostate cancer diagnostic strategy has to be validated. However, one way of improving identification in patients referred for screening might be pre-biopsy MRI, which would provide guidance for targeting biopsies. A 'targeted biopsies only' strategy (that is, without systematic biopsies) may reduce the number of biopsies (indicated only in patients with positive imaging), therefore avoiding the potentially unnecessary diagnosis of insignificant cancer. Any prospective, randomised trial testing MRI as an adjunct or replacement for biopsies will need to be carefully designed to include cost-utility and cost-effectiveness analysis of imaging.
targeted biopsies strategy and has the potential to improve biopsy results by increasing the detection of clinically significant cancers, reducing the detection of clinically insignificant cancers and giving a more representative sampling of cancer (length and grade). The purpose of this article is to summarise the main current imaging techniques used for the diagnosis of localised prostate cancer and their role in patients with suspected prostate cancer.
Ultrasound Techniques

Transrectal Ultrasonography
TRUS is widely used to guide systematic transrectal prostate biopsy procedures. This imaging technique is effective for lesions located in the peripheral zone (PZ), but the observed heterogeneity of the transition zone (TZ) during TRUS prevents consistent detection of TZ cancers. In a study by Toi et al., suspicious lesions detected during TRUS significantly increased the likelihood of cancer detection by a factor of 1.8 (57.8 % versus 30.8). 8 Likewise, subsequent biopsies from these lesions had an increased median percentage of cancer involvement in each biopsy core compared with randomly acquired biopsies (50 % versus 10 %, p<0.001) and were more likely to have a Gleason grade of 7 or higher (69.3 % versus 28.3 %, p<0.001). 9 However, no specific information was provided by the authors about biopsy location (anterior versus posterior gland). In another study, consisting of 544 patients with abnormal PSA and a prostate cancer prevalence of 35 %, TRUS was found to have sensitivity and specificity of 41 % and 85 %, respectively. 10 The positive predictive value of TRUS for prostate cancer identification in this study was as low as 53 %, highlighting the usefulness of such an imaging modality. A computer-based TRUS has been investigated 11, 12 and has shown potential to improve prostate cancer diagnosis, but further data are needed to confirm this finding. 
Multiparametric Magnetic Resonance Imaging
Multiparametric MRI (mp-MRI) of the prostate obtained prior to biopsy in patients with suspected prostate cancer was shown to be effective in both anterior and posterior zones of the gland 2,16,17 (see Figure 1 ). In an extended series and using radical prostatectomy histopathology as a reference standard test, the sensitivity and specificity of mp-MRI for identifying significant cancer foci (i.e., with tumour volume>0.5 cm 3 )
in clinically localised disease (including anterior prostate cancers)
were 86 % and 94 %, respectively. 2 The negative predictive value was 95 %. Mean cancer volume detected at MRI was 2.44 ml (range 0.02-14.5) and mean cancer volume not detected at MRI was 0.16 ml (range 0.01-2.4). However, the use and diffusion of mp-MRI requires a degree of discipline in its conduct, reporting and evaluation. A recent European MRI Consensus Panel 16 recommended that this modern imaging modality needs to be delivered in a quality-controlled manner with uniformly high standards and used as a test prior to biopsy.
T2-weighted, dynamic contrast-enhanced and diffusion-weighted MRI
were the key sequences incorporated into the minimum requirements but spectroscopy was not recommended. A five-point scale was agreed upon for specifying the probability of malignancy, with a minimum of 16-27 prostatic sectors of analysis to include a pictorial representation of suspicious foci (see Figure 2) .
Targeting Biopsies to a Suspicious Area
Targeting biopsies to an MRI-suspicious area was proven to be very effective in improving detection of anteriorly located cancers, which represent 20 % of the largest cancers in unselected patients suspected to have prostate cancer, beyond the area sampled by posterior biopsies. 2, 18 This was true whether tissue biopsy was performed under MRI-directed realtime biopsy (MRI guidance) 19 or under TRUS guidance with MRI 'cognitive' co-registration. 18 Also, the sensitivity of biopsy for high-grade disease should be improved with biopsies targeted to MRI lesions. 18 
Implication for Active Surveillance
The gap between active surveillance for an insignificant cancer and focal therapy for an isolated significant but low-risk cancer is narrow. 27 Thus, MRI implication for active surveillance may be limited to insignificant cancer cases as defined above and not detected at MRI.
Assessing the negative predictive value for significant volume cancer is therefore critical. As mentioned above, MRI can identify sides or zones without significant cancers.
2,28
Future Implications
The optimal prostate cancer diagnostic strategy for early-stage cancers would be one that features both low morbidity and low cost in the reliable identification of cancers presenting potential harm to To address this concept of pre-biopsy MRI, 555 consecutive patients with suspected prostate cancer had pre-biopsy 1.5-Tesla mp-MRI with pelvic coil, 10-12 TRUS-guided systematic biopsies plus two targeted biopsies at any MRI area suspected to be malignant. 29 Targeted biopsies were performed under TRUS guidance, based on the MRI standardised report (see Figure 2 ) and on prostatic zonal anatomy landmarks. Dickinson, et al., 2011. 16 targeted biopsies. Of the 302 cancers detected, 82 % were significant and 18 % were insignificant. Detection accuracy of significant cancers by targeted biopsies was higher than that of systematic biopsies (p<0.001).
Targeted biopsies also detected 16 % more grade 4/5 cases and better quantified the cancer than systematic biopsies, with median cancer length of 5.6 mm versus 4.7 mm (p=0.001). This series showed that a 'targeted biopsies only' strategy (that is, without systematic biopsies) would have necessitated an average of 3.8 core biopsies performed in only 63 % of patients with positive MRI and would have avoided the potentially unnecessary diagnosis of 13 % of insignificant cancers.
A medico-economic evaluation of pre-biopsy MRI has not been carried out. However, such an analysis is necessary because a pre-biopsy MRI strategy would cost about €300 per patient (in Europe) and would require available MRI and experienced radiologists. Pre-biopsy MRI that studies the pelvic nodes can be, in the case of cancer, the only imaging modality for pretreatment evaluation beside bone scan, which is indicated if PSA>10 ng/ml or Gleason grade 4 cancer is present. 29 In the study by Haffner et al., 29 cancer was diagnosed in 54 % of cases. No other imaging was performed for local and pelvic staging. It should be emphasised that, in 46 % of cases with no cancer at biopsy, a non-suspicious MRI has 94 % specificity for significant (>0.5 cm 3 )
cancer identification, which is valuable for further biopsy indication and may reduce the number of unnecessary additional biopsies.
Conclusion
Use of realtime elastography, CECD-US and mp-MRI in prostate cancer management is controversial and current guidelines underplay the role of these techniques. Technological advances over the past 5 years demand a re-evaluation of current practice. Before these advances can be implemented into routine protocols, they must be validated in prospective trials. The economic implications for using these recently developed imaging modalities in all patients who require a prostate biopsy also need careful consideration. Any prospective, randomised trial will need to be carefully designed to include cost-utility and cost-effectiveness analysis. MRI also plays a role in selecting and monitoring patients who undergo surveillance, focal therapy or organ-sparing therapy guided by imaging. n 
